Abstract: Proposed is a method of preparing glucaric acid from glucose through TEMPO oxidation. The method of preparing glucaric acid includes (a) reacting glucose in a solvent through an oxidation reaction using 4-acetamido-TEMPO serving as a nitroxide radical-mediated organocatalyst, potassium bromide serving as a co-catalyst, and potassium hypochlorite serving as an oxidizing agent to prepare glucaric acid. The method can improve the conversion efficiency of glucose to glucaric acid through optimal conditions of the temperature, pH, and input of the oxidizing agent in an oxidation reaction using a TEMPO acid catalyst.

Abstract: Disclosed is a method for preventing or treating muscular atrophy or sarcopenia, the method comprising administering a composition comprising 2?-fucosyllactose (2?-FL) as an active ingredient to a subject in need thereof. The composition administered to the subject increases the expression of genes related to mitochondrial function enhancement and mitochondrial biosynthesis, and reduces the expression of atrogin-1 and MuRF1 genes, which are markers for muscular atrophy, thereby providing effects of strengthening muscles and preventing muscular atrophy or sarcopenia.

Abstract: Disclosed is a composition for promoting hair growth and ameliorating, preventing or treating hair loss containing 2?-fucosyllactose (2?-FL) as an active ingredient, and a method for promoting hair growth or ameliorating, preventing or treating hair loss, the method comprising administering to a subject in need thereof 2?-fucosyllactose. Treatment with a combination of testosterone and 2?-fucosyllactose increases hair gloss, increases hair length, reduces a hair loss area, enhances hair cuticles, increases the number and size of hair follicles, and improves expression of proteins and genes related to hair proliferation and growth, compared to treatment with testosterone alone, thus being applicable as a substance for various food and pharmaceutical compositions based on effects of promoting hair growth, improving hair loss, and ameliorating, preventing or treating hair loss.

Abstract: Disclosed is a composition containing 2?-FL for ameliorating, preventing or treating diseases caused by reduction of dopamine. 2?-FL has an advantage of effectively preventing or treating diseases caused by a decrease in dopamine by effectively suppressing degeneration of dopaminergic neurons. In particular, the composition of the present invention is effective in preventing, treating, or ameliorating Parkinson's disease caused by reduction of dopamine because it contains 2?-fucosyllactose (2?-FL) as an active ingredient, thereby suppressing the decrease in dopaminergic neurons and exhibiting an effect of improving motor activity.

Abstract: Disclosed is a composition for promoting hair growth and ameliorating, preventing or treating hair loss containing 2?-fucosyllactose (2?-FL) as an active ingredient, and a method for promoting hair growth or ameliorating, preventing or treating hair loss, the method comprising administering to a subject in need thereof 2?-fucosyllactose. Treatment with a combination of testosterone and 2?-fucosyllactose increases hair gloss, increases hair length, reduces a hair loss area, enhances hair cuticles, increases the number and size of hair follicles, and improves expression of proteins and genes related to hair proliferation and growth, compared to treatment with testosterone alone, thus being applicable as a substance for various food and pharmaceutical compositions based on effects of promoting hair growth, improving hair loss, and ameliorating, preventing or treating hair loss.

Abstract: Disclosed is a method for, preventing, ameliorating or treating dementia by administering a composition containing 2?-fucosyllactose. 2?-FL ameliorates brain damage caused by amyloid beta and neuroinflammation by suppressing or preventing accumulation of the amyloid beta, thus being highly effective in preventing, ameliorating and treating dementia.

Abstract: Disclosed is fucosyllactose having antiviral activity and inhibitory activity against viral infection, and a method for preventing or treating a viral infection by administering a composition including fucosyllactose as an active ingredient to a subject in need thereof. It was found that 2?-fucosyllactose and 3-fucosyllactose, which are human milk oligosaccharides (HMOs), have antiviral activity, and in particular, 3-fucosyllactose in vitro and in vivo exhibits much higher antiviral activity and inhibitory activity against viral infection compared to 2?-fucosyllactose and is thus useful as an antiviral agent.

Abstract: The present invention relates to a method for increasing the productivity of 2?-fucosyllactose through various changes in culture medium composition and culturing on the basis of lactose, which is a substrate, wherein 2-fucosyllactose can be continuously produced in a high-yield at an optimum lactose concentration discovered by a culturing method of the present invention.

Abstract: Disclosed is a mucoadhesive pharmaceutical composition comprising a poly-ionic complex of chitosan and a polyacrylic acid polymer. As an oral formulation, the composition has the extended retention time in the gastrointestinal tract by its mucoadhesive and swelling properties, which is useful as sustained release formulations, retentive formulations of active ingredients with limited absorption regions, and active ingredients with pH dependent solubility.

Abstract: Disclosed are a food composition containing 2?-fucosyllactose and a pharmaceutical composition containing 2?-fucosyllactose that are effective in ameliorating, preventing or treating various cerebro-cardiovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebro-cardiovascular disease caused by a thrombus by administering a composition including 2?-fucosyllactose (2?-FL) to a subject in need thereof. The 2?-fucosyllactose (2?-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

Abstract: Disclosed is a method for improving the productivity of 2?-fucosyllactose (2?-FL) through enzymatic treatment. Lactose used as a substrate in the stationary phase during culture is degraded by treatment with a small amount of enzyme, the resulting glucose is consumed to produce guanosine diphosphate-L-fucose as a precursor of 2?-fucosyllactose, and the use of lactose left after culture can be maximally utilized for the production of 2?-fucosyllactose. As a result, it is possible to increase the productivity of 2?-fucosyllactose in an economically efficient manner because additional glucose is not required while minimizing by-products.

Abstract: Disclosed is a method for improving the productivity of 2?-fucosyllactose (2?-FL) through enzymatic treatment. Lactose used as a substrate in the stationary phase during culture is degraded by treatment with a small amount of enzyme, the resulting glucose is consumed to produce guanosine diphosphate-L-fucose as a precursor of 2?-fucosyllactose, and the use of lactose left after culture can be maximally utilized for the production of 2?-fucosyllactose. As a result, it is possible to increase the productivity of 2?-fucosyllactose in an economically efficient manner because additional glucose is not required while minimizing by-products.

Abstract: Disclosed is a method for preventing or treating muscular atrophy or sarcopenia, the method comprising administering a composition comprising 2?-fucosyllactose (2?-FL) as an active ingredient to a subject in need thereof. The composition administered to the subject increases the expression of genes related to mitochondrial function enhancement and mitochondrial biosynthesis, and reduces the expression of atrogin-1 and MuRF1 genes, which are markers for muscular atrophy, thereby providing effects of strengthening muscles and preventing muscular atrophy or sarcopenia.

Abstract: Disclosed are a food composition containing 2?-fucosyllactose and a pharmaceutical composition containing 2?-fucosyllactose that are effective in ameliorating, preventing or treating various cerebrovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebrovascular disease caused by a thrombus by administering a composition including 2?-fucosyllactose (2?-FL) to a subject in need thereof. The 2?-fucosyllactose (2?-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

Abstract: Disclosed is fucosyllactose having antiviral activity and inhibitory activity against viral infection, and a method for preventing or treating a viral infection by administering a composition including fucosyllactose as an active ingredient to a subject in need thereof. It was found that 2?-fucosyllactose and 3-fucosyllactose, which are human milk oligosaccharides (HMOs), have antiviral activity, and in particular, 3-fucosyllactose in vitro and in vivo exhibits much higher antiviral activity and inhibitory activity against viral infection compared to 2?-fucosyllactose and is thus useful as an antiviral agent.

Abstract: Disclosed is an operation method for a dynamic analyzer for analyzing an execution state of a web application. The present invention comprises the steps of: analyzing an execution state of the web application on the basis of a final attack string including a parameter which indicates a particular operation to be executed through the web application; and performing an analysis of the execution state of the web application, wherein the final attack string is generated so as to avoid filtering logic which is designed to filter a raw attack string including a predefined parameter. Therefore, the present invention can detect a security vulnerability, which cannot be detected by the existing dynamic analyzer, through easy generation of a final attack string capable of bypassing filtering.

Abstract: Disclosed is a method for producing 2?-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2?-fucosyllactose at a high concentration, high yield and high productivity.

Abstract: Disclosed is a mucoadhesive pharmaceutical composition comprising a poly-ionic complex of chitosan and a polyacrylic acid polymer. As an oral formulation, the composition has the extended retention time in the gastrointestinal tract by its mucoadhesive and swelling properties, which is useful as sustained release formulations, retentive formulations of active ingredients with limited absorption regions, and active ingredients with pH dependent solubility.

Abstract: Disclosed is a food or pharmaceutical composition containing 2?-fucosyllactose (2?-FL) for preventing a stroke. The food or pharmaceutical composition containing 2?-fucosyllactose (2?-FL) is highly effective in preventing a stroke.

Abstract: Disclosed is a method for producing 2?-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2?-fucosyllactose at a high concentration, high yield and high productivity.